Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins.
We report the use of recombinant scorpion toxins in the form of fusion proteins as antigens for immunisation in rabbits and mice: the aim was to produce in these animal models protective antisera against the most lethal alpha-type toxins in the venom from the North African scorpion Androctonus australis. The cDNAs encoding AaH I, AaH II and AaH III (the three major alpha-type toxins acting on voltage-sensitive sodium channels) were fused to the sequence encoding the maltose binding protein (MBP). The constructs (MBP-AaH I, MBP-AaH II, MBP-AaH I+II and MBP-AaH III) were expressed in Escherichia coli, and resulting fusion proteins were translocated to the periplasmic space. The recombinant fusion proteins were characterised and used as antigens to generate antibodies in rabbits. These antibodies raised specifically recognised their corresponding radiolabelled-toxin with affinities in the 0.1nM range. In vitro neutralisation assays indicated that 1ml of serum raised against a mixture of fusion proteins was able to neutralise 15 LD(50) of the toxic fraction (AaH-G50) purified from the crude venom by molecular filtration through Sephadex G50. In vivo, the fusion proteins induced a long-term protection in mice against the lethal effects of AaH-G50 or of the native toxins. Ten weeks after the beginning of the immunisation programme, mice were challenged with various toxins or AaH-G50 doses. Mice were fully protected against three LD(50) of AaH-G50. Our work shows that fusion protein constructs can be used as a vaccine providing efficient immune protection against A. australis venom.
Legros
C
C
CNRS UMR 6560, Laboratoire de Biochimie, Institut Jean Roche, Faculté de Médecine Nord, Université de la Méditerranée, Bd Pierre Dramard, 13916 Marseille Cedex 20, France.
Kaabi
H
H
El Ayeb
M
M
Céard
B
B
Vacher
H
H
Bougis
P E
PE
Martin-Eauclaire
M F
MF
D000818:Animals; D000906:Antibodies; D001483:Base Sequence; D018076:DNA, Complementary / Q000235:genetics; D006801:Humans; D007114:Immunization; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009479:Neuropeptides / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology / Q000633:toxicity; D009498:Neurotoxins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology / Q000633:toxicity; D009500:Neutralization Tests; D010957:Plasmids / Q000235:genetics; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D030162:Reptilian Proteins; D012604:Scorpion Venoms / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology* / Q000633:toxicity*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
D000906:Antibodies; D018076:DNA, Complementary; D009479:Neuropeptides; D009498:Neurotoxins; D011993:Recombinant Fusion Proteins; D030162:Reptilian Proteins; D012604:Scorpion Venoms; D014614:Vaccines, Synthetic; C067223:scorpion toxin AaH III; C065314:scorpion toxin I, Androctonus; C053969:scorpion toxin II, Androctonus